Kardiologie up2date 2009; 5(1): 14-18
DOI: 10.1055/s-0028-1119673
Hotline – Herzinsuffizienz

© Georg Thieme Verlag KG Stuttgart · New York

BEAUTIfUL-Studie – Analyse der Studienergebnisse

Marco  Albanese, Wolfgang  Schoels
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. März 2009 (online)

Abstract

The results of the BEAUTIfUL-Study presented at the ESC meeting in Munich last year showed the following:

The use of Ivabradine in patients with coronary heart disease and left-ventricular dysfunction in combination with beta-blockers is safe and beneficial as an adjunct to standard therapy. A heart rate ≥ 70 beats/minute is associated with an impaired prognosis regarding cardiovascular death, hospitalisation for heart failure, revascularization and for myocardial infarction, and also regarding the primary composite of cardiovascular death, non-fatal myocardial infarction and hospitalisation for heart failure. As a consequence, heart rate should be routinely assessed in daily practice and taken into account as an additional risk factor. In patients with an initial heart rate ≥ 70 beats/minute, Ivabradine significantly reduces the need for subsequent revascularizations and the number of myocardial infarctions. As an add-on to standard therapy, Ivabradine might exert additional prognostically relevant effects, which complement the known benefical effects on ischaemia-related symptoms in patients with a heart rate > 60 beats/minute.

Literatur

Dr. med. Dr. Marco Albanese
Prof. Dr. med. Wolfgang Schöls

Klinik für Kardiologie und Angiologie
Herzzentrum Duisburg

Gerrickstraße 21
47137 Duisburg

eMail: malbanes@ejk.de